At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 342 enrolled
Drug / intervention
Nemonoxacin +5 moredrug
Likely dose
Placebo (250 ml)from record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An International, Multicenter, Randomized, Double-blind, Double-dummy, Two-way, Parallel Group, Controlled Study to Compare the Efficacy and Safety of Intravenous and Oral Nemonoxacin Versus Tavanic® in Adult Patients With Community-acquired Pneumonia
In Brief
A Phase 3 clinical trial evaluating Nemonoxacin, Tavanic, and 2 other interventions for Pneumonia, Bacterial. Completed, enrolled 342 participants across 25 sites.
Detailed Summary
The primary objective of this study was to evaluate the clinical efficacy of treatment with Nemonoxacin compared with Tavanic® in patients with community-acquired pneumonia (CAP).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPneumonia, Bacterial
CountriesRussia
CollaboratorsOCT Clinical Trials
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
Primary CompletionDec 2017
Study CompletionDec 2017
First PostedJun 2018
TodayJul 2026
First PostedJun 11, 2018
Enrollment StartMay 4, 2016
Primary CompletionDec 13, 2017
Study CompletionDec 26, 2017
TodayJul 2, 2026
Enrollment to primary: 1.6 yearsPosted 8.1 years ago
Interventions
Nemonoxacindrug
Solution for infusion, 500 mg (250 ml)
Nemonoxacindrug
Capsules, 250 mg
Tavanicdrug
Solution for infusion, 500 mg (100 ml)
Tavanicdrug
Film coated tablets (each tablet is placed into a capsule shell (overencapsulated) for blinding purposes), 250 mg
Placebo (250 ml)drug
0.9% NaCl (250 ml), solution for infusion
Placebo (100 ml)drug
0.9% NaCl (100 ml), solution for infusion